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Resection of Primary Mediastinal Non-Seminomatous Germ
Cell Tumors
A 28-Year Experience at Memorial Sloan-Kettering Cancer Center
Inderpal S. Sarkaria, MD,* Manjit S. Bains, MD,* Shelly Sood, BA,* Camelia S. Sima, MD,†
Victor E. Reuter, MD,‡ Raja M. Flores, MD,§ Robert J. Motzer, MD, George J. Bosl, MD,
and Valerie W. Rusch, MD*
Introduction: Surgical resection of residual tumor mass in respond-
ers to platinum-based chemotherapy has evolved as the preferred
treatment of primary mediastinal nonseminomatous germ cell tu-
mors (PMNGCTs). We reviewed a single institution’s operative
experience with these rare tumors.
Methods: We reviewed charts of patients resected for PMNGCT at
Memorial Sloan-Kettering Cancer Center between July 1980 and
April 2008. Analyses included Kaplan-Meier survival with univar-
iate log-rank comparisons and Cox multivariate regression.
Results: Fifty-seven patients were identified and followed up for a
median of 5.3 years. Fifty-four of them received platinum-based
preoperative chemotherapy, and 28 (49%) had limited stage I/II
disease. Preoperative tumor markers normalized or decreased in
79% of patients. The most common surgical approach was antero-
lateral thoracotomy with partial sternotomy (“hemiclamshell,”
38.6%). An R0 resection was achieved in 91% of the patients with
a major morbidity of 17.5% and no postoperative deaths. The
median overall survival was 31.5 months. Factors correlating with
better survival on univariate analyses were necrosis or teratoma
versus residual cancer on final pathology (p  0.001), R0 resection
(p 0.03), normalized or decreased postchemotherapy/preoperative
tumor markers (p  0.001), normalized postoperative tumor mark-
ers (p 0.004), stage I/II disease (p 0.03), and surgery after 2000
versus 1980–1999 (p  0.01). An exploratory multivariate analysis
suggests that normalized or decreased postchemotherapy/preopera-
tive tumor markers is the strongest independent predictor of im-
proved survival.
Conclusions: In a cohort of PMNGCT patients in which 91% of the
patients underwent complete posttherapy resection, response to
chemotherapy, measured by normalized or decreased preoperative
tumor markers, was the strongest predictor of improved survival.
Key Words: Germ Cell Tumor, Mediastinal Mass, Tumor Markers,
Surgery.
(J Thorac Oncol. 2011;6: 1236–1241)
Primary mediastinal nonseminomatous germ cell tumors(PMNGCTs) are primarily a disease of children and
young men, usually presenting in the second to fourth de-
cades of life. Mediastinal origin of NSGCTs is in and of itself
considered an independent predictor of poor prognosis com-
pared with those of gonadal origin.1 Although rare, the
diagnosis should be considered in any young male with an
anterior mediastinal mass and may represent up to 5% of
anterior mediastinal masses in adults and 10 to 15% in
children. There are several histological types including em-
bryonal carcinoma, yolk sac carcinoma, choriocarcinoma,
teratoma, and mixed types containing seminomatous compo-
nents combined with elements of those previously mentioned.
Nonseminomatous and nonteratomatous subtypes account for
15% of these tumors, teratomas 45%, combined subtypes
5%, and pure seminomas 35%.2
These large anterior mediastinal masses often present
with pain and compression syndromes such as pericardial
tamponade or superior vena cava syndrome. Although prior
histological diagnosis by means of surgical biopsy or large or
fine-bore needle is preferable, treatment may be started on the
basis of increased tumor markers. Serum alpha fetoprotein is
increased in up to 80% of NSGCTs and beta-human chorionic
gonadotropin (-HCG) in up to 35% of NSGCTs.
The mainstay of treatment is aggressive, multidrug
chemotherapy. Surgery is largely considered an adjuvant
treatment for resection of tumor residua in patients respond-
ing to chemotherapy. At certain specialty centers, surgery is
considered even in cases of chemotherapy nonresponders,
given the overall ineffectiveness of second-line chemother-
apy and lack of other good treatment options.3,4 Despite
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treatment, outcomes are generally poor, with 5-year survival
rates reported between 30 and 48%.1,4–7
The purpose of this study was to analyze a single
institution’s surgical experience with PMNGCT. Our primary
goals were to identify significant predictors of outcome and
survival in a surgical cohort resected at a single major referral
center and to examine the operative approaches to resection
of these tumors.
METHODS
We retrospectively reviewed the medical records of
patients with PMNGCT resected at Memorial Sloan-Ketter-
ing Cancer Center (MSKCC) from 1980 to 2008. Data from
nonoperative patients and those not resected at our institution
were not collected and are beyond the scope and intent of this
study. Data points collected included basic patient demo-
graphics, method of preoperative diagnosis/biopsy, informa-
tion on preoperative chemotherapy regimens, alpha fetopro-
tein, -HCG, and lactate dehydrogenase tumor marker status
(including prechemotherapy, postchemotherapy/preoperative,
and postresection), operative data (including surgical ap-
proach and resection details), tumor stage, pathology (includ-
ing preoperative biopsy and postresection histology), and
survival outcomes.
All preoperative and operative biopsies were reviewed
at MSKCC. All death events were confirmed by online search
of the Social Security Death Index. All patients were required
to have their primary resection at MSKCC. Decisions to
proceed with surgery were at the joint discretion of the
oncologist and surgeon. In general, patients considered for
resection are those with response to chemotherapy docu-
mented by normalized or decreased tumor markers and with
tumor residua felt to have reasonable potential for complete
resection. Nevertheless, given the absence of viable alterna-
tive treatment options, selected patients with increasing tu-
mor markers and disease burden with potential for complete
resection may also be offered surgery.
A previously described staging system by Moran and
Suster2 was adapted to postoperatively stage patients based
on pathology reports of the resected specimen (Table 1).
Time to recurrence, overall survival (OS), and progression-
free survival (PFS) from time of surgery were estimated using
the Kaplan-Meier method. Comparison between groups was
performed by log-rank test (for univariate analysis) and Cox
proportional hazards regression stratified by surgery period
(before 2000 versus 2000) (for multivariate analysis). Al-
though small sample size prohibited robust multivariable testing,
an exploratory multivariate analysis was performed. This study
was approved by the MSKCC Internal Review Board.
RESULTS
Patient and Tumor Characteristics
Fifty-seven patients undergoing primary resection for
PMNGCT at MSKCC between July 1980 and April 2008
were identified. Demographics and results are summarized in
Table 2. Fifty-six of the patients (98.2%) were male, and the
median age was 30 years (range 18–50 years). The median
postoperative follow-up time among patients who did not die
was 5.3 years (range 0–14 years). The most common method
of preoperative biopsy was anterior mediastinotomy (Cham-
berlain procedure) (28/57, 49%), and the most common
preoperative tumor histologies were mixed PMNGCT (21/56,
43%) and Yolk Sac tumors (16/56, 29%). All except three
patients received preoperative chemotherapy with a combi-
nation of bleomycin, etoposide, and cis-platinum or etopo-
side, ifosfamide, and cis-platinum. Preoperative tumor mark-
ers were normalized or decreased in 81.8% (45/55) of
patients; 42.1% (24/57) presented with metastatic disease
before treatment, most often to the lung.
Surgery and Complications
Details of surgery and complications are outlined in
Table 2. A single surgeon (M.S.B.) performed 65% of the
resections; 88% were performed by three surgeons. Thirty-six
patients (63%) were resected by anterior thoracotomy with
partial median sternotomy (hemiclamshell) or bilateral ante-
rior thoracotomy with transverse sternotomy (clamshell) sur-
gical approaches. The median length of surgery was 240
minutes (range 120.0–480.0 minutes). Estimated median
blood loss was 510 mL (range 11.0–2200.0 mL). The median
length of hospital stay was 7 days (range 4–47 days). Lung
(41/57, 71.9%) and pericardium (39/57, 68.4%) were the
most common additional structures resected with the tumor.
An R0 (complete macroscopic and microscopic) resection was
accomplished in 91% (49/54) of patients. Ten patients (17.5%)
experienced grade 3 or 4 complications, according to the Com-
mon Terminology Criteria for Adverse Events version 3.0.8 In
cases where severity of morbidity could not be ascertained from
chart review, major morbidity (grade 3 or 4) was assumed. There
were no deaths within the 30-day perioperative period.
Recurrence and Survival
Twenty-six patients recurred, with a median time to
recurrence of 15 months (95% confidence interval [CI]:
4.8–not reached). Single-site recurrence occurred in 19 pa-
tients: four in the mediastinum, six in the lungs, four in bone,
two in liver, two in brain, and one in the chest wall. Com-
bined mediastinal and lung recurrence occurred in four pa-
tients. One patient presented with combined liver, lung, and
mediastinal recurrence, and one with back (soft tissue), me-
diastinal, and pleural recurrence. Recurrence was diagnosed
in one patient based on increasing -HCG levels with no
identifiable site of tumor growth.
TABLE 1. PMNGCT Staging
Stage I Well circumscribed tumor without microscopic invasion into
adjacent structures
Stage II Tumor confined to mediastinum with macroscopic and/or
microscopic infiltration into adjacent structures (pleura,
pericardium, great vessels)
Stage III Tumor with metastases
IIIA Metastases to intrathoracic sites (lymph nodes, lung, etc.)
IIIB Metastases to extrathoracic sites
Adapted from Cancer. 1997;80:681–690.
PMNGCT, primary mediastinal nonseminomatous germ cell tumors.
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Patients included in the cohort had a median survival of
4.5 months (range 1–24 months) between start of chemotherapy
and surgery. The median OS after start of chemotherapy was
33.8 months. Although we report this as an estimate of survival
from time of chemotherapy, we caution that this median is not
truly comparable with estimates reported in unselected groups
inclusive of patients who start chemotherapy but do not progress
to surgery. Instead, it only applies to patients who live long
enough and are deemed operable after their chemotherapy treat-
ment, and comparisons to survival results in patients receiving
chemotherapy alone are fraught with bias.
Patients who did not die during the study time were
followed for a median of 5.3 years after surgery. Twenty-six
deaths were observed, only four of which occurred without
prior recurrence. The median PFS and OS from time of
surgery were 9.1 and 31.5 months, respectively. PFS and OS
at 2 years were 46 and 56%, respectively (Figure 1).
Predictors of improved OS on univariate analysis in-
cluded the presence of necrosis or teratoma versus residual
carcinoma in the final specimen (p  0.001; Figure 2), Stage
I/II versus IIIA/IIIB (p  0.03; Figure 3), normalized or
decreased postchemotherapy/preoperative (p 0.001; Figure
4) and postresection markers (p  0.004), and R0 versus
R1/R2 resection (p  0.03). In addition, patients who had
FIGURE 1. Overall survival and progression-free survival.
Variable N/Total Evaluable (%)
Final pathology stage
Stage I 11/52 (21.2%)
Stage II 17/52 (32.7%)
Stage IIIA 22/52 (42.3%)
Stage IIIB 2/52 (3.8%)
Final pathology
Necrosis 15/57 (26.3%)
Teratoma 12/57 (21.1%)
Cancer 30/57 (52.6%)
STM, serum tumor markers; AFP, alpha fetoprotein; -HCG, beta-human chorionic
gonadotropin; CTCAE, common terminology criteria for adverse events; SVC, superior
vena cava.
TABLE 2. Patient, Tumor, and Treatment Characteristics
Variable N/Total Evaluable (%)
Median age (yr) 30 (18–50)
Gender, male 56/57 (98.2%)
Preoperative biopsy
Chamberlain 28/57 (50%)
Fine needle aspiration 11/57 (20%)
Core needle biopsy 5/57 (9%)
Other 13/57 (21%)
Preoperative histology on biopsy
Mixed 24/56 (43%)
Yolk sac 16/56 (29%)
Teratoma 4/56 (7%)
Embryonal 2/56 (3%)
Choriocarcinoma 1/56 (2%)
Other 9/56 (16%)
Median prechemotherapy STM
AFP (ng/mL) 899 (0–66,500)
-HCG (mIU/mL) 0 (0–17,052)
Preoperative STM
Normalized or falling 45/55 (81.8%)
Rising 10/55 (18.2%)
Preoperative chemotherapy 54/57 (94.7%)
Metastatic disease 24/57 (42.1%)
Lungs 23/57 (40.4%)
Liver 2/57 (3.5%)
Brain 2/57 (3.5%)
Bone 2/57 (3.5%)
Non-mediastinal lymph nodes 2/57 (3.5%)
Other 4/57 (8.8%)
Operative approach
Hemiclamshell 22/57 (38.6%)
Clamshell 14/57 (24.6%)
Median sternotomy 18/57 (31.6%)
Posterolateral thoracotomy 3/57 (5.3%)
Additional structures resected
Lung 41/57 (71.9%)
Pericardium 39/57 (68.4%)
Phrenic nerve 12/57 (21.1%)
Large vessels 6/57 (10.5%)
Diaphragm 3/57 (5.3%)
Heart/atrium 2/57 (3.5%)
Other 10/57 (17.5%)
Completeness of resection
R0 49/54 (90%)
R1 3/54 (6%)
R2 2/54 (4%)
CTCAE Grade 3 or 4 morbidity 10/57 (17.5%)
Pulmonary embolism 2/57 (3.5%)
Pneumonia 2/57 (3.5%)
Stroke 1/57 (1.8%)
Endocarditis 1/57 (1.8%)
Phrenic nerve palsy 1/57 (1.8%)
Renal failure 1/57 (1.8%)
Sepsis 1/57 (1.8%)
SVC thrombosis 1/57 (1.8%)
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surgery more recently (year 2000 and later) had better sur-
vival compared with patients treated before year 2000 (p 
0.01). Limited sample size prevented a reliable, robust mul-
tivariate analysis allowing for inclusion of all factors to be
significant in our univariate analysis. In a limited, exploratory
multivariate analysis stratified by period of surgery (2000
versus 2000), having increasing preoperative tumor mark-
ers (hazard ratio  3.2; 95% CI  1.1–9.4; p  0.04) was
independently associated with worse survival (Table 3). The
other two variables included in the model (final pathology
and pathological staging) approached but did not reach sta-
tistical significance (p values 0.05 and 0.07, respectively).
Although all the factors mentioned above, with the exception
of the pathological stage, were univariately associated with
PFS, having residual carcinoma in the final specimen was the
only predictor in an exploratory-adjusted multivariate analysis
(hazard ratio  5.0; 95% CI  1.6–15.1; p  0.005; Table 4).
DISCUSSION
PMNGCT remains an aggressive disease of young men
with poor survival. Lack of durable response and resistance to
first-line chemotherapy regimens, associated hematologic ma-
lignancies, and malignant transformation of the primary tumor to
nongerm cell tumor elements have been cited as reasons for
these poor outcomes.9–14 In addition, no factors have been found
that can reliably and selectively identify patients with no remain-
ing viable cancer in tumor residua after initial treatment.15
Postchemotherapy adjuvant surgery with the goal of resecting all
tumor residua has evolved as a mainstay of therapy in the hopes
of achieving durable remission in these patients.4,12,15
This study represents the surgical experience with
PMNGCT at a single specialty center with operations per-
formed by a limited number of highly experienced surgeons,
with exclusion of patients receiving resections of their pri-
mary mass at outside institutions. Overall, results of this
study are largely congruent with the findings of previous
reports from other similar centers (and our own), citing
postchemotherapy/preoperative and postoperative normaliza-
tion of tumor markers, complete (R0) resection of all tumor
residua, the absence of extramediastinal disease (i.e., limited
stage), and absence of residual viable tumor in the resected
specimen as factors predictive of better outcomes.3–7,10,12,14
Vuky et al.,4 in a previous report from our institution, re-
ported a 2-year survival rate of 38% in patients undergoing
resection. Predictors of worse survival on univariate analysis
included persistent malignancy in the postresection specimen,
the need for extramediastinal resection, and increasing
postchemotherapy markers. Multivariate analyses were not
reported. A larger, more recent experience in 158 patients by
Kesler et al.6 from Indiana University found persistent tumor
in the resection specimen and increased postresection mark-
ers to be associated with worse survival on multivariate
analysis. Of note, 11% of the 158 patients in this study were
resected at outside institutions.
As mentioned, this study largely confirms the findings
of these studies, with univariate analyses identifying preop-
FIGURE 2. Overall survival by pathology in the final speci-
men (necrosis or teratoma versus residual carcinoma).
FIGURE 3. Overall survival by pathological stage (I/II versus
IIIA/IIIB).
FIGURE 4. Overall survival by perioperative change in tu-
mor markers (normalized or decreased versus increased).
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erative and postoperative normalization or decrease in tumor
markers, complete (R0) tumor resection, absence of extrame-
diastinal disease (as represented by limited stage I/II), and
absence of tumor in the pathological specimen to be associ-
ated with improved OS. All the mentioned factors, with the
exception of stage, also correlated with improved PFS. Our
exploratory multivariate analysis identified normalizing or
decreasing preoperative tumor markers as independent pre-
dictors of better OS, with limited pathological stage and
absence of cancer in the residual tumor also approaching
statistical significance. Not surprisingly, only absence of
tumor in the resected specimen showed a strong association
with PFS on multivariate analysis.
Although our cohort spans over almost three decades,
there were no remarkable changes in the chemotherapy pro-
tocols or patient demographics during this time. Nevertheless,
TABLE 3. Factors Associated with OS on Univariate and Multivariate Analysis
N Median OS (mo) OS at 2 yr
Univariate
Analysis p
Multivariate Analysis
HR (95% CI) p
Year 0.01 Stratification factor
2000–2008 28 Not reached 0.72
1980–1999 29 10.4 (5.4–not reached) 0.41
Final pathology 0.001
Necrosis/teratoma 27 Not reached 0.83 1 Ref
Cancer 30 9.1 (5.8–31.5) 0.33 3.2 (1.0–10.0) 0.05
P stage 0.03
I/II 28 Not reached 0.69 1 Ref
III/IV 24 10.1 (5.3–not reached) 0.41 2.4 (0.9–5.9) 0.07
Preoperative marker 0.001
Normalized/falling 45 Not reached 0.63 1 Ref
Rising 10 5.6 (1.4–10.1) 0.15 3.2 (1.1–9.4) 0.04
Postoperative marker 0.004 Not included in the model
Normalized/falling 38 Not reached 0.62
Rising 11 8.3 (3.9–13.2) 0.14
Complete resection 0.03 Not included in the model
R0 49 2.4 (1.4–not reached) 0.4
R1/R2 5 Not reached 0.61
OS, overall survival; CI, confidence interval; HR, hazard ratio.
TABLE 4. Factors Associated with PFS on Univariate and Multivariate Analysis
N Median PFS (mo) PFS at 2 yr
Univariate
Analysis p
Multivariate Analysis
HR (95% CI) p
Year 0.03 Stratification factor
1980–1999 29 5.2 (1.9–18) 0.30
2000–2008 28 Not reached 0.62
Final pathology 0.001
Necrosis/teratoma 27 Not reached 0.75 1 Ref
Cancer 30 3 (1.8–6.5) 0.21 5.0 (1.6–15.1) 0.005
P stage 0.31
I/II 28 35.4 (2.6–not reached) 0.55 1 Ref
III/IV 24 5.2 (1.8–not reached) 0.37 1.1 (0.5–2.5) 0.85
Preoperative marker 0.002
N/F 45 35.4 (5.2–not reached) 0.51 1 Ref
R 10 2.3 (0.7–3.4) 0.1 2.4 (0.9–6.1) 0.07
Postoperative marker 0.001 Not included in the model
N/F 38 Not reached 0.54
R 11 2.2 (1.5–3) 0.09
Complete resection 0.01 Not included in the model
R0 49 Not reached 0.51
R1/R2 5 2.4 (1.5–3) 0.2
PFS, progression-free survival; CI, confidence interval; HR, hazard ratio.
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it is expected that the cumulative surgeon and institutional
experience with these patients, improvements in periopera-
tive and critical care, and possible changes in patient selec-
tion for resection may have impacted the chance of survival
over time. We stratified the analysis by surgery period, which
accounts for potential secular trends in the baseline risk of
death of PMNGCT patients.
Although certainly influenced by the study’s retrospec-
tive nature, reported major morbidity was relatively low, with
no mortality within the 30-day postoperative period. Our
surgical approach heavily favors a hemiclamshell or clam-
shell exposure to insure maximal exposure of all affected
structures and best chance of complete resection. As we have
previously reported, this approach has been shown to afford
excellent exposure to the mediastinum and bilateral lung
fields, which is required in the resection of these locally
aggressive tumors often involving lung and other mediastinal
structures.16 This approach is well tolerated by patients with
minimal or no respiratory compromise attributable to the
sternotomy and/or anterior thoracotomies.
With this approach, complete microscopic and macro-
scopic (R0) resection of tumor was achieved in 91% of
patients and was found to be a significant predictor of
survival on univariate survival (having only five patients with
incomplete resection prevented the inclusion of this variable
in the univariate model). As mentioned above, the importance
of complete resection of all tumor residua has been echoed in
other reports, with durable survival outcomes (although van-
ishingly rare) seen even in the face of increased tumor
markers or enlarging masses before surgery.3,4 Our staging
schema was found to be a prognostic factor on univariate
analysis only and is not likely to add much clinical relevance
or benefit. In our opinion, it is best used as a marker of
extramediastinal disease, a known predictor of worse out-
comes in these patients.
In summary, complete radical resection of residual tumor
mass after platinum-based chemotherapy for PMNGCT can be
accomplished in most of appropriately selected patients with
normalized or decreased tumor markers and may offer mean-
ingful long-term survival benefits. Nevertheless, given poor
alternative options in this aggressive disease, surgery may also
be offered even to patients with increasing postchemotherapy
markers if it is thought complete resection can be accomplished.
Unfortunately, hope for cure remains bleak in this subset of
patients and supports ongoing investigation of other salvage
modalities for primary treatment failure.
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